Aileron Therapeutics grabs $33 mln Series E

Aileron Therapeutics has raised $33 million in Series E funding. The investors included AJU IB Investment Co., Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund and SR One. Based in Cambridge, Mass., Aileron Therapeutics is a clinical stage biopharmaceutical firm that is developing therapeutics based on its proprietary Stapled Peptide drug platform.

North AmericaUSBriefs